Abstract:Cancer immunotherapy with ICB is considered a promising strategy for cancer treatment. In silico prediction of the ICB response is an important step toward achieving effective and personalized cancer immunotherapy. Three challenging issues remain: (i) Identifying highly predictive biomarkers by deciphering and understanding the interaction between tumor and immune cells; (ii) efficiently obtaining and predicting these biomarkers using HTS data; and (iii) building effective computational models that integrate these biomarkers for improved ICB response prediction. Cancer immunotherapy with immune-checkpoint blockade (ICB) is considered a promising strategy for cancer treatment. Identifying predictive biomarkers and developing efficient computational models to predict the ICB response are important issues for successful immunotherapy. Here, we present a concise and intuitive survey of the computational issues for ICB response prediction, providing a summary of the available predictive biomarkers and building of one-stop machine-learning models that integrate biomarkers calculable from high-throughput sequencing (HTS) data. Several points for discussion are highlighted to inspire further research for improving ICB treatment. Continuing efforts are required to improve ICB response prediction and to identify novel predictive biomarkers by taking advantage of the rapid development of computational models and HTS techniques for effective and personalized cancer immunotherapy. Cancer immunotherapy with immune-checkpoint blockade (ICB) is considered a promising strategy for cancer treatment. Identifying predictive biomarkers and developing efficient computational models to predict the ICB response are important issues for successful immunotherapy. Here, we present a concise and intuitive survey of the computational issues for ICB response prediction, providing a summary of the available predictive biomarkers and building of one-stop machine-learning models that integrate biomarkers calculable from high-throughput sequencing (HTS) data. Several points for discussion are highlighted to inspire further research for improving ICB treatment. Continuing efforts are required to improve ICB response prediction and to identify novel predictive biomarkers by taking advantage of the rapid development of computational models and HTS techniques for effective and personalized cancer immunotherapy. immune checkpoints are molecules in the immune system that either enhance or attenuate a signal. Tumors protect themselves from the immune system by inhibiting the T cell signal. The use of inhibitors to block inhibitory checkpoint molecules by recovering the anticancer immune response is referred to as ‘immune checkpoint blockade’. peptides presented by MHC class I or MHC class II molecules on the tumor cell surface. These peptides derive from tumor-specific somatic mutations and are not expressed in normal cells. the cellular environment in which the tumor exists, including surrounding blood vessels, immune cells, fibroblasts, bone marrow-derived inflammatory cells, lymphocytes, signaling molecules, and the extracellular matrix. The tumor and surrounding microenvironment are closely related and constantly interact. Effective immunotherapy often requires changes to the TME. V-J recombination is the unique mechanism of genetic recombination that occurs in developing lymphocytes during the early stages of T and B cell maturation. It involves somatic recombination in a nearly random fashion, which rearranges variable (V), joining (J), and, in some cases, diversity (D) gene segments. This has resulted in the highly diverse repertoire of antibodies and/or immunoglobulins (Igs) and T cell receptors (TCRs) found on B cells and T cells, respectively.

Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade

Research progress and clinical application of predictive biomarker for immune checkpoint inhibitors

Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies

Predictive Biomarkers for Tumor Immune Checkpoint Blockade

Predicting patient outcomes after treatment with immune checkpoint blockade: A review of biomarkers derived from diverse data modalities

Predictive Biomarkers for Cancer Immunotherapy with Immune Checkpoint Inhibitors

Predictive biomarkers for checkpoint blockade-based immunotherapy

Research progress of anti-PD-1 / PD-L1 immunotherapy biomarkers

Advances and prospects of biomarkers for immune checkpoint inhibitors

Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy

Progresses in biomarkers for cancer immunotherapy

Crosstalk Between the Tumor Microenvironment and Cancer Cells: A Promising Predictive Biomarker for Immune Checkpoint Inhibitors

Immune checkpoint inhibitors: recent progress and potential biomarkers

FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients

Predictive Biomarkers of Immune Checkpoint Inhibitor Response in Breast Cancer: Looking beyond Tumoral PD-L1

The development of biomarkers for cancer immunotherapy

Towards in Silico Prediction of the Immune-Checkpoint Blockade Response

Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities

Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1

Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges

Potential non-invasive biomarkers in tumor immune checkpoint inhibitor therapy: response and prognosis prediction